Pharmafile Logo
Pharmafocus logo
Advanced Search

hepatitis C

Showing 15 posts of 65 posts found.

800px-european_commission_flags

European Commission approves first drug for hepatitis D

August 6, 2020
Business Services EC, hepatitis C, hepatitis D

The European Commission has approved Heplcudex (bulvirtide) as the first hepatitis D drug. It was jointly developed by researchers at …

News
abbvie_0

AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients

September 27, 2019
Medical Communications, Sales and Marketing AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma

The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the …

News
5204602349_c87b204860_z

FDA warns three Hepatitis C drugs may worsen liver function in some rare cases

August 29, 2019
Medical Communications, Research and Development AbbVie, FDA, Gilead, HCV, MSD, hepatitis C, public health

The FDA has warned that three Hepatitis C (HCV) drugs made by AbbVie, Gilead and MSD are worsening liver function …

News

FDA approves AbbVie’s Mavyret for children with Hepatitis C (HCV)

May 1, 2019
Research and Development AbbVie, HCV, hepatitis C, mavyret, pharma

The FDA has approved AbbVie’s Mavyret tables (glecaprevir/pibrentasvir) as a treatment for hepatitis C (HCV) in children aged 12 to 17 …

News
opioid_pills

Reformulated OxyContin led to spike in Hepatitis C infections

February 5, 2019
Manufacturing and Production OxyContin, USA, hepatitis C, heroin, infectious diseases, opioids

Efforts to create an “abuse deterrent” OxyContin pill inadvertently led to an increase in the number of Hepatitis C infections, …

News
abbvie_0

AbbVie’s case against the NHS thrown out of court

January 22, 2019
Manufacturing and Production AbbVie, HCV, NHS, health, hepatitis C, public health

A judge has thrown US multinational AbbVie’s case against NHS England’s hepatitis C procurement process, out of court. Mr Justice …

News
gilead-sciences

Gilead to release generic versions of hep C meds over a decade before patent expiry

September 28, 2018
Medical Communications, Sales and Marketing Epclusa, Gilead, generics, harvoni, hepatitis C, pharma

Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of …

News
shutterstock_92671375

US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute

April 26, 2018
Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi

MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

April 13, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Cancer, Humira, Mylan, Novartis, Shire, Takeda, Teva, acquisition, cystic fibrosis, hepatitis C, pharma, top ten

It’s Friday the 13th, but that doesn’t change a strong showing from the industry this week as it continued to …

News
hcv_credit_bruceblaus

New hepatitis C combo boasts 97% cure rate for just $300

April 12, 2018
Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …

News
gilead-sciences

Gilead launches hep C drug Sovaldi in China at one-fifth of US price

November 29, 2017
Research and Development, Sales and Marketing China, Gilead, hepatitis C, pharma, sovaldi

Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it …

News
merck_incweb

MSD pulls out of hep C space to Gilead’s relief

October 2, 2017
Sales and Marketing MSD, biotech, drugs, hepatitis C, pharma, pharmaceutical

MSD, known as Merck in North America, has announced that it will curtail its attempts to make an impact in …

News

J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion’s stock

September 12, 2017
Manufacturing and Production, Sales and Marketing J&J, JJ, Johnson & Johnson, achillion, hepatitis C, pharma

Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to …

News
world_hep_day

Nine in 10 people unaware they have hepatitis

July 28, 2017
Medical Communications, Research and Development Gilead, biotech, drugs, hepatitis, hepatitis C, pharma, pharmaceutical

The WHO has released a report on the state of hepatitis prevention and treatment to mark World Hepatitis Day, with …

News
exit-1722888_960_720

Regulus CEO heads to exit as company struggles with FDA hold

May 5, 2017
Medical Communications, Research and Development Regulus, hepatitis C

Regulus seemed to be in a good place just last year as its lead drug candidate performed well in a …

News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024